Case Study

Improving Screening and Identifying Therapeutic Targets for NAFLD

Metabolon offered a comprehensive solution to investigate whether nonalcoholic fatty liver disease (NAFLD) is heritable, whether there is a shared gene-effect with hepatic steatosis and fibrosis, and if gut-derived metabolites mediate this shared gene-effect.

These results suggest a common genetic basis underlying the susceptibility towards NAFLD-related fibrosis and 3-(4-hydroxyphenyl)lactate pathway and their joint association with the gut microbiome. Targeting specific nodal points in this metabolic pathway could have a major therapeutic impact on NAFLD.

Talk With An Expert About Your Project

The Challenge: Improving Screening and Identifying Therapeutic Targets for NAFLD

Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat accumulates in the liver of people who drink little or no alcohol. It is currently recognized as one of the world’s most common etiologies of chronic liver disease. NAFLD is a form of hepatic steatosis that can progress to hepatic fibrosis. Given the epidemic increase of NAFLD cases and its association with high morbidity and mortality, there is a need to better characterize the heritability of NAFLD to understand its pathogenesis, identify potential therapeutic targets, and improve the screening of the patients who are at a higher risk of progression to hepatic fibrosis. Metabolomics can provide new insights into the molecular mechanisms of diseases, including NAFLD.

Metabolon Insight: Uncovering Shared Gene-Effect with Hepatic Steatosis and Fibrosis

This study utilized the Metabolon Global Discovery Panel to profile sera from a twin and family cohort with (n = 36) and without (n = 120) NAFLD.¹ Among the NAFLD individuals, 36 had hepatic steatosis and 28 had progressed to liver fibrosis. The Global Discovery Panel’s unrivaled coverage of up to 5,400 metabolites offered this group the most comprehensive solution to investigate whether NAFLD is heritable, whether there is a shared gene-effect with hepatic steatosis and fibrosis, and if gut-derived metabolites mediate this shared gene-effect.

The Solution: Metabolomics Identifies a Gut Microbiome Derived Metabolite Associated with NAFLD

Metabolomics detected 1,181 metabolites in the serum of the twin and family cohort. Among the 713 metabolites analyzed, 153 belonging to eight super pathways (eg, amino-acid, lipid, and carbohydrate) were significantly differentially expressed in individuals with NAFLD compared to individuals without NAFLD, and 86 belonging to eight super pathways were significantly differentially expressed in individuals with liver fibrosis compared to individuals without fibrosis.

This research group then used a twin additive genetics and unique environment effects model to estimate the shared gene-effect. Among the 713 serum metabolites analyzed in the twins, 440 serum metabolites were heritable. Among the 440 heritable serum metabolites identified, 170 serum metabolites had a significant shared gene-effect with hepatic steatosis and 94 serum metabolites had a significant shared gene-effect with hepatic fibrosis. Among them, 56 serum metabolites had a significant shared gene-effect with hepatic steatosis and fibrosis. Interestingly, among these 56 serum metabolites, six metabolites had a microbial origin and derived potentially from the gut microbiome: 3-(4-hydroxyphenyl)lactate, N-formylmethionine, phenyllactate, mannitol, allantoine, N-(2-furoyl)glycine. Finally, these findings were validated in an independent validation cohort of 156 participants with liver biopsy-proven NAFLD. Among all metabolites, only 3-(4-hydroxyphenyl)lactate was significantly associated with hepatic fibrosis in this cohort.

The Outcome: Elucidating a Novel Biomarker of NAFLD

Utilizing the twin and family cohort and a validation cohort of patients with biopsy-proven NAFLD, this study reports the association between a gut microbiome-derived serum metabolite, 3-(4-hydroxyphenyl)lactate that has a statistically and clinically significant shared gene-effect with both hepatic steatosis and fibrosis. These results suggest a common genetic basis underlying the susceptibility towards NAFLD-related fibrosis and 3-(4-hydroxyphenyl)lactate pathway and their joint association with the gut microbiome. Targeting specific nodal points in this metabolic pathway could have a major therapeutic impact on NAFLD. In addition, 3-(4-hydroxyphenyl)lactate could be a useful biomarker for the screening of patients at risk of an advanced stage of NAFLD or could be used for monitoring the targeted therapeutic response when modulating the microbiome to affect hepatic fibrosis in NAFLD.

References

1. Caussy C, Hsu C, Lo MT, et al. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. Sep 2018;68(3):918-932. doi:10.1002/hep.29892

Related Case Studies

See All Case Studies

Metabolomics finds PanK4 to be an Important Regulator of Glucose Uptake and Lipid Metabolism

Find out more $

Metabolomics provides insight into the pathology of sudden infant death syndrome and identifies biomarker candidates

Find out more $

Metabolomics Reveals Beneficial Changes to Metabolite Profiles During Diabetes Remission

Find out more $

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.